Novel Influenza Vaccines Work Group

Rationale

- Two FDA-licensed H5N1 vaccines
 - Need for recommendations for use during nonpandemic period
 - Need to review evidence for use in certain high-risk groups
- ACIP was seen as the most appropriate body to develop recommendations for these vaccines
- Seasonal influenza work group focuses on seasonal influenza vaccines (full plate)

Status of Work Group

- Work group formed
- First call completed
- Meet every two weeks initially then monthly as needed
- Anticipate reporting in October 2014 with possible vote in February 2015
- Future of work group to be determined after initial task completed

Work Group

Organization	Organization
ACIP Members Doug Campos-Outcalt Ruth Karron Jon Temte	Chair Chair, Influenza Work Group Chair, ACIP
Liaisons Kathy Neuzil Matthew Zahn	IDSA NACCHO
Consultants Wendy Keitel John Treanor Rick Bright	BARDA
CDC Sonja Olsen (CDC Lead) Joe Bresee, Rubin Donis, Lisa Grohskopf, Jackie Katz, Leslie Sokolow, Tim Uyeki, Julie Villanueva Tom Shimabukuro Sam Graitcer	CDC, Influenza Division CDC, Influenza Division CDC, Immunization Safety Office CDC, Immunization Services Division
Ex Officio Members Jesse Geibe Marion Gruber Linda Lambert, Kanta Subbarao Bruce Gellin	DoD FDA NIH NVPO